iPSC-derived Lactocytes for Sustainable Human Milk Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human milk are limited by the reliance on human donors, which is not sustainable or practical, and existing infant formulas cannot replicate the complex composition of human milk, especially in terms of bioactive components like lactoferrin and oligosaccharides.
Innovation Solution
The method involves generating lactocytes from mammalian induced pluripotent stem cells (miPSC) and expressing a mammalian milk-like product, such as human milk, from mammary-like gland organoids, allowing for the production of a customized and bioactive-rich milk product that can complement existing infant nutrition solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human donors are used to produce human milk, then the milk composition is authentic and complete, but the source is limited and unsustainable
Solution Approach 1:
The patent creates an in vitro copy of human mammary gland tissue using iPSC-derived organoids that replicate the lobulo-alveolar structure and milk-producing functionality. This copying approach allows production of authentic human milk components without relying on human donors, resolving the contradiction between composition authenticity and production sustainability
Solution Approach 2:
The patent transforms the production system by changing the biological parameter from human donor dependence to iPSC-based in vitro generation. By altering the cell source and cultivation conditions, the system maintains authentic milk composition while achieving sustainable, scalable production
2Productivity
If current manufacturing processes are used for infant formula, then production is scalable, but the milk composition cannot replicate human breastmilk
Solution Approach 1:
The patent changes the manufacturing approach from conventional formula production to iPSC-based organoid cultivation. By adjusting cultivation parameters and differentiation conditions, the system achieves both scalability and precise replication of human milk composition including bioactive components
Solution Approach 2:
The patent creates a composite in vitro system combining iPSCs, extracellular matrix components, and growth factors to form functional mammary organoids. This composite approach enables complex milk composition production while maintaining scalable cultivation protocols
3Adaptability or versatility
If hBSC are used to produce human breast milk, then differentiation into mammary lineages is achieved, but the method requires human donors and is not practical
Solution Approach 1:
The patent replaces hBSC with iPSC as the cell source, creating a copy of the stem cell functionality that does not require human donors. The iPSC-derived organoids replicate the differentiation capability into mammary lineages while eliminating donor dependence, improving ease of manufacture
Solution Approach 2:
The patent makes the cell source universal by using iPSCs that can be derived from various human tissues and differentiated into mammary lineages. This multi-functional cell source eliminates the need for specific human donors while maintaining differentiation capability
Data Source
AI summary
A method for producing a mammalian milk like product, for example a human milk like product comprising generating lactocytes derived from mammalian induced pluripotent stem cells (miPSC), for example human induced pluripotent stem cells (hiPSC), and expressing the mammalian milk like product, for example the human milk like product from lactocytes.